Peripheral artery disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BTK 9
• GLP-1 1
• SGLT2 1
• PCSK9 1
• APOE 0
• HIF-1 0
• PPAR 0
• VEGF 0
• AKT 0
• ERK 0
• ABL1 0
• CCR5 0
• IL-17 1
• IL-6 0
• KEAP1 0
• NLRP3 0
• NRF2 1
• PTEN 0
• RUNX1 0
• STAT3 0
• TNF 0
• TP53 0
• TREM2 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · R44

  Development and Chronic Preclinical Assessment of a Flexible Endovascular Scaffold for Treating Stenosis in the Femoropopliteal Arterial Segments

  Ev2 Technologies, Inc.· Pittsburgh, United States· US$918,166 awarded in fiscal year 2026· until Aug 2028

• NIH NHLBI · R01

  Immune-mediated mechanisms of VEGF-A165 alternative splicing in angiogenesis in the context of Advanced Aging

  Ocean State Research Institute, Inc.· Providence, United States· US$514,340 awarded in fiscal year 2026· until May 2031

• NIH NHLBI · R43

  Development of combined U-turn catheter and self-anchoring sheath system for turning direction of established percutaneous vascular access

  Upstream Access, Inc· Camden, United States· US$320,893 awarded in fiscal year 2026· until Mar 2027

• NIH NIA · R21

  Urolithin A to Improve Mitochondria and Mobility in Peripheral Artery Disease: Urolithin for PAD Trial

  Northwestern University· Chicago, United States· US$214,006 awarded in fiscal year 2026· until Aug 2028

• NIH NIBIB · F32

  Bedside oximetry system for minimally invasive quantitative measurement and monitoring of tissue oxygenation.

  Dartmouth College· Hanover, United States· US$76,780 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  From niche to function: how endothelial cell interactions orchestrate muscle function in health and disease (InterECt)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €2,498,888· until Apr 2032

• European Commission (Horizon Europe) · HORIZON-ERC

  Single cEll guided polygeniC Risk prEdicTion of ASCVD (SECRET)

  Ita-Suomen Yliopisto· Kuopio, Finland· EU contribution €2,000,000· until Jun 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEase (MIRACLE)

  Ita-Suomen Yliopisto· Kuopio, Finland· EU contribution €4,599,866· until Sept 2027· 6 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  PERSONALIZED REHABILITATION VIA NOVEL AI PATIENT STRATIFICATION STRATEGIES (PREPARE)

  Aristotelio Panepistimio Thessalonikis· Thessaloniki, Greece· EU contribution €5,774,113· until May 2027· 9 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  DEVELOPING TRUSTWORTHY ARTIFICIAL INTELLIGENCE (AI)-DRIVEN TOOLS TO PREDICT VASCULAR DISEASE RISK AND PROGRESSION (VASCUL-AID)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €5,969,125· until Apr 2029· 10 countries

10 of 216 running projects, newest first. Listed amounts together: US$125.2m + €20.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 18
• CRISPR-Cas Systems 1
• Gene Expression Profiling 5
• Proteomics 9
• Metabolomics 6
• Flow Cytometry 1
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 9
• Machine Learning 18
• Deep Learning 5
• Cohort Studies 53
• Genome-Wide Association Study 22

• Non-contrast ultrashort echo time magnetic resonance imaging-guided staging predicts in vivo lower extremity endovascular procedural complexity.

  J Vasc Surg, Jul 2026

• Foot dynamic contrast-enhanced MRI for assessing microcirculatory changes after endovascular therapy in peripheral artery disease: A prospective pilot study.

  Magn Reson Imaging, Jul 2026

• Self-enhancement-based perfusion mapping with contrast-enhanced magnetic resonance imaging for PAD assessment.

  Magn Reson Imaging, Apr 2026

• Blood oxygenation level-dependent MRI in critical limb-threatening ischemia: association with clinical and angiographic findings and response to revascularization.

  Jpn J Radiol, Mar 2026

• Exploring the Dynamics of Ischemia and Reactive Hyperemia With Skeletal Muscle Blood Oxygen Level Dependent MRI in Patients With Peripheral Artery Disease, Age-Matched Controls, and Young Healthy Subjects.

  J Magn Reson Imaging, Jan 2026

• Systemic and local risk factors for major amputation following diabetic minor amputation.

  Foot Ankle Surg, Jan 2026

• Significant improvement of neurological and radiological findings caused by multiple lateral meningocele by cyst-subarachnoid shunt in a 6-year-old boy: case report.

  Childs Nerv Syst, Dec 2025

• Simvastatin augments revascularization and reperfusion in a murine model of hind limb ischemia - Multimodal imaging assessment.

  Nucl Med Biol, Nov 2016

• The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.

  Atherosclerosis, Apr 2011

See which targets of this disease your abstract mentions, and go to the people working on them.